Experimental drug more effective in treating rare kidney disease
Thursday, October 25, 2018 - 21:00
in Health & Medicine
New study finds that experimental drug sparsentan is an effective treatment for the rare kidney disease focal segmental glomerulosclerosis, which currently has no FDA-approved therapies.